2Q17 Quarterly Commentary

Our style was not in favor in the quarter as cheap valuation characteristics were a headwind. Bond surrogates outperformed as long term interest rates fell despite solid economic growth. This underweighted cohort sells at an 800 basis point price per earnings premium to non bond surrogate stocks despite lower earnings growth rates.